香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年7月1日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

证券简称：昭衍新药 证券代码：603127 公告编号：2025-026 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立基金 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、与专业投资机构合作参与投资设立产业基金情况概述 北京昭衍新药研究中心股份有限公司（以下简称"昭衍新药"、"公司"）于 2024 年 12 月 20 日召开第四届董事会第十一次会议，审议通过了《关于公司与专业投 资机构合作参与投资设立基金的议案》，同意公司或指定子公司以不超过 2,000 万人民币投资参与华夏致远创业投资基金（北京）合伙企业（有限合伙）（暂定 名）（以下简称"本基金"、"合伙企业"）的发起设立。华夏股权投资基金管 理（北京）有限公司为本基金的普通合伙人、执行事务合伙人，并担任本基金的 基金管理人。具体内容详见公司于 2024 年 12 月 21 日在上海证券交易所网站 （www.sse.com.cn）及指定信息披露媒体《上海证券报》披露的《昭衍新药关于 与专业投资机构合作参与投资设立基金的公告》（公告编号： ...

Core Insights - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on the entire chain from research and development to payment systems [1] - The inclusion of innovative drug directories in commercial health insurance is expected to enhance the multi-tiered medical security system and provide economic support for the development of innovative drugs [1][2] - The stock market reacted positively, with significant gains in innovative drug concept stocks and ETFs, indicating strong investor interest and liquidity in this sector [1][2] Industry Developments - The establishment of a commercial insurance innovative drug directory marks a significant step in enhancing the role of commercial insurance in the multi-tiered medical security system, providing payment support for high-priced innovative drugs and medical devices [2] - The "18A" policy has catalyzed a wave of medical companies listing in Hong Kong, focusing on cutting-edge medical industry directions, which has attracted market attention and investment [2] Market Performance - The Hong Kong innovative drug ETF (513120) saw a rise of over 2%, with a trading volume of 4.1 billion yuan, leading the market in the pharmaceutical ETF category [1] - The latest scale of the Hong Kong innovative drug ETF reached 13.4 billion yuan, indicating its leading position in the market [1] - The innovative drug ETF (515120) also performed well, with a trading volume of 145 million yuan and a net inflow of nearly 200 million yuan over five consecutive days [1]

Core Viewpoint - The A-share pharmaceutical sector experienced a significant rally, with notable stocks such as Saily Medical hitting the daily limit, Rongchang Bio rising over 7%, and Shutai Shen increasing by more than 6% due to supportive government measures for innovative drug development [1] Group 1 - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs [1] - The new measures include the use of medical insurance data to facilitate the research and development of innovative drugs [1]

Market Overview - The Shanghai Composite Index closed at 3444.43 points, above the five-day moving average, with a gain of 0.59% [1] - The total trading volume of A-shares reached 1,517.37 billion yuan [1] Stocks Performance - A total of 664 A-shares have surpassed the five-day moving average, indicating positive momentum [1] - Notable stocks with significant deviation rates include: - Morningstar Airlines (15.14%) - Xiangyu Medical (14.86%) - Qifeng Precision (13.27%) [1][2] - Stocks with smaller deviation rates that just crossed the five-day moving average include: - China Duty Free Group - Shanghai Yizhong - Shanjin International [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the five-day moving average: - Morningstar Airlines: 19.99% increase, 15.14% deviation [2] - Xiangyu Medical: 20.01% increase, 14.86% deviation [2] - Qifeng Precision: 17.25% increase, 13.27% deviation [2] - Other notable stocks include: - Lianjian Optoelectronics: 19.92% increase, 10.74% deviation [2] - Songsheng Co.: 13.73% increase, 10.55% deviation [2]

Group 1 - The CSI Medical Index (399989) has shown a strong increase of 1.17%, with significant gains in constituent stocks such as Zhaoyan New Drug (603127) reaching a 10% limit up, and Kylin Pharmaceutical (002821) rising by 5.71% [1] - The leading medical ETF (560260) has experienced a 1.60% increase, with a trading volume of 16.8873 million yuan and an average daily trading volume of 14.2868 million yuan over the past year [1] - The leading medical ETF has achieved a net value increase of 9.14% over the past year, with the highest monthly return since inception being 29.94% and an average monthly return of 8.25% [1] Group 2 - As of May 30, 2025, the top ten weighted stocks in the CSI Medical Index account for 55.09%, with notable companies including WuXi AppTec (603259) and Mindray Medical (300760) [2] - The medical outsourcing service sector is expected to see a rebound, driven by its core position in the industry chain, valuation advantages, and signs of recovery in market conditions [2] - Despite the CRO industry facing challenges, the new listing policies on the Sci-Tech Innovation Board are anticipated to change market perceptions regarding the future development of the CRO sector [2]

Market Overview - The A-share market saw all three major indices rise in the morning session, with the Shanghai Composite Index up 0.2%, the Shenzhen Component Index up 0.54%, and the ChiNext Index up 0.93% [1] - The total market turnover reached 932.6 billion yuan, a decrease of 81.1 billion yuan compared to the previous day, with over 3,500 stocks rising [1] Sector Performance - The gaming, military, brain-computer interface, and photolithography concept stocks led the gains, while the banking, securities, and dairy sectors experienced declines [3] - Notable stocks in the military sector included Hengyu Xintong (300965), Chenxi Aviation (300581), and Zhongbing Hongjian (000519), all of which hit the daily limit [3] - The gaming sector saw significant increases with Kaiying Network (002517) and Giant Network (002558) both reaching the daily limit [3] - Photolithography concept stocks were active, with Blue Eagle Equipment (300293) hitting the daily limit, along with Kaimete Gas (002549) and Zhongci Electronics (003031) [3] - The innovative drug sector rebounded, with Zhaoyan New Drug (603127) also hitting the daily limit [3] - The banking and securities sectors faced early declines, with Guosheng Jinkong (002670) dropping over 5% [3] Hot Stocks - The strongest sectors included new energy vehicles, military, and specialized innovative companies, with multiple stocks hitting daily limits [8][9][10] - In the new energy vehicle sector, 16 stocks reached the daily limit, with the highest consecutive limit being 9 days [8] - The military sector had 14 stocks hitting the daily limit, with the highest consecutive limit also being 9 days [9] - The specialized innovative sector had 13 stocks hitting the daily limit, with a maximum of 3 consecutive limits [10] Sector Insights - The military equipment sector is expected to benefit from increasing global military trade demand and domestic military modernization efforts, potentially leading to a dual boost in fundamentals and industry valuations [12] - The gaming sector is supported by a record number of game approvals, indicating regulatory support for healthy industry development [13] - The brain-computer interface sector is gaining attention due to advancements from Neuralink, with significant usage data reported from trial participants [14] - The digital currency sector is poised for growth as Hong Kong aims to enhance cross-border payment efficiency through stablecoins, with new regulations set to take effect [15]

Core Viewpoint - The report from Industrial Securities highlights that China's innovative drugs possess high efficiency and low-cost development advantages, particularly in popular technology areas such as ADC, bispecific antibodies, and cell therapy, indicating a competitive edge in the industry [1] Group 1: Stock Performance - Zhaoyan New Drug reached the daily limit increase, while Tigermed, Haoyuan Medicine, and Kylin Pharmaceutical rose over 5% [1] - Other companies such as Jinkai Biotechnology, WuXi AppTec, Sunshine Nuohe, and Kanglong Chemical also experienced upward movement in their stock prices [1] Group 2: Industry Insights - The report emphasizes that the current competitive advantages in the innovative drug sector are expected to continue showcasing industry competitiveness [1]

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

司股份数量为101,714股，占公司股份总数的0.02%，最高成交价为人民币79.3元/ 股，最低成交价为人民币75.5元/股，成交总金额为人民币7,997,727.28元（不含 交易费用）。回购方案实际执行与已披露的方案不存在差异，公司已按照披露的 方案完成回购。具体内容详见公司于2022年9月2日在上海证券交易所网站 （www.sse.com.cn）及公司指定信息披露媒体《上海证券报》披露的《昭衍新药 关于回购股份方案实施完成暨股份变动的公告》（公告编号：2022-076）。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-025 北京昭衍新药研究中心股份有限公司 关于减少注册资本暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 北京昭衍新药研究中心股份有限公司（以下简称"公司"）于2023年3月30 日召开的第四届董事会第二次会议及第四届监事会第二次会议审议通过了《关于 公司终止实施2021年A股员工持股计划的议案》，于2023年10月30日召开的第四 届董事 ...